Serum Concentration Of Sialic Acid Research Articles

Comparison effects of platelet-rich plasma on healing of infected and non-infected excision wounds by the modulation of the expression of inflammatory mediators: experimental research.

Microbial invasion in soft tissue is believed to cause infectious wounds and increase healthcare costs, anxiety, and distress. The current study was conducted to evaluate the effects of topical use of platelet-rich plasma (PRP) on infected wound-healing process in rats. Following the induction of a circular wound, the animals were divided into three groups, including (1) standard control: infected wounds treated with mupirocin (SDCL), (2) non-infected wounds treated with PRP (PRP), and (3) infected group in which the rats were infected with Staphylococcus epidermidis and Pseudomonas aeruginosa and treated with PRP (INF + PRP). To evaluate the effects of PRP on the wound-healing rate, total bacterial count, histopathological assessment, the serum concentrations of sialic acid, C-reactive protein, haptoglobin, and fibrinogen were assessed. Additionally, IL-1β, IL-6, TNF-α, IL-3, NF-κB, iNOS, PDGF, and EGF mRNA level expressions were assessed employing the qRT-PCR method. The results indicated that topical application of PRP could significantly decrease total bacterial count, the level of C-reactive protein, and pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) compared to the SDCL group. The administration of PRP also promoted re-epithelization rate by increasing the expression of EGF mRNA level. We could recommend the use of PRP for the treatment of infected wounds owing to its efficiency in decreasing colonization of tissue bacteria, tissue inflammation, and stimulating wound heal-up.

Variations in the mRNA expression level of UDP-GlcNAc epimerase/ManNAc kinase and neuraminidase 1 genes in organs of type 2 diabetic animals.

Sialic acid and its associated metabolic enzymes have emerged as important components of the pathophysiology of type 2 diabetes (T2D). There is an elevation in the serum concentration of sialic acid in humans and animals with T2D. The present study investigated the modulation of mRNA expression level of UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (GNE) and neuraminidase 1 (NEU1) genes in some organs of type 2 diabetic rats. T2D was induced using fructose-streptozotocin model and eight weeks after the induction of diabetes, sialic acid was assayed in the blood and organs (adipose tissue, brain, colon, kidney, liver, pancreas, skeletal muscle and spleen) followed by quantification of mRNA expression level of GNE and NEU1 genes by qPCR. The results showed a significant (P < 0.05) increase in sialic acid level in the serum and all the afore-mentioned organs investigated except in the adipose tissue and skeletal muscle of the diabetic rats compared the normal control. The expression GNE gene was only increased in the pancreas (1.8-fold) of the diabetic rats while there was a decrease in the expression of the gene in the colon. In contrast, the expression of NEU1 gene was increased in the spleen (3.5-fold), brain (2.2-fold), liver (1.9-fold), colon (1.5-fold) and kidney of the diabetic rats. It was concluded that the elevated level of sialic acid in the organs of diabetic rats, except the pancreas, might not be due to increased endogenous synthesis of sialic acid.

Evaluation of L-fucose and Sialic Acid Levels in Patients With Colorectal Cancer and Control Subject

Background: Currently, glycans, which are known as functional molecules in the biological system, are being under study as potential cancer markers. This study aimed to determine the level of serum L-fucose and sialic acid as the biomarkers in patients with colorectal cancer (CRC). Materials and Methods: The patients with CRC (n=40, 20 men and 20 women) participated in the present study. The spectrophotometric method was used to measure the levels of L-fucose and sialic acid in the serum of the patients. SPSS (version 21) was used to analyze the obtained data. The results were expressed as mean ± SD. Results: The mean ± SD L-fucose level in patients with CRC was 27.46 ± 4.8 ng/mL, which was more than this level in the healthy control group (18.64±3.1 ng/mL). Also, the mean ± SD serum concentration of sialic acid in patients with CRC was 2.1 ± 0.41 ng/mL, which was more than the mean ± SD sialic acid level of 1.23±0.21 ng/mL in the healthy controls. Conclusion: Serum concentration of L-fucose and sialic acid increased significantly (P &lt; 0.05) in patients with CRC compared with the healthy controls. We believe that determining serum L-fucose and sialic acid levels could be useful for the detection of CRC patients in the early stage.

Variation of total serum sialic acid concentration in postmenopausal women.

Given its location and ubiquitous distribution, sialic acid can mediate or modulate a wide variety of physiological and pathological processes; however, there is scarce data regarding the associations between sialic acid serum levels and sex, age and menopause. The present study evaluated the age-related changes in serum sialic acid (SA) levels in 97 elderly subjects, including men and postmenopausal women. A significant increase in serum levels of sialic acid in postmenopausal women and a significant decrease in men were observed in an age-dependent manner. Furthermore, in postmenopausal women, positive correlations were observed between the total serum sialic acid level and age in all decades and subgroups. The total serum concentration of sialic acid in the postmenopausal women group exhibited a particular pattern; significantly lower levels were observed in subjects in the intermediate postmenopausal period compared with those in the first decade of post menopause and then higher levels again as the women get older (late climax), thus the concentration increased according to the age of the individual.

The concentration of total sialic acid in chronic hepatitis B and C.

The synthesis and glycosylation of glycoproteins and glycolipids take place in the liver. Thus, liver diseases may affect serum concentrations of some carbohydrate derivatives, especially the concentration of sialic acid which is attached to the end of oligosaccharide chains. The aim of this study was to measure and compare the serum concentration of total sialic acid in chronic hepatitis B and C. The hypothesis is that both viruses responsible for the development of inflammation work differently at the cellular level. Serum samples were obtained from 90 patients suffering from liver diseases: 50 from chronic hepatitis B and 40 from chronic hepatitis C at the time of diagnosis. The total sialic acid concentration in the serum was measured according to the enzymatic method using a colorimetric procedure. The mean total sialic acid concentration in patients with chronic hepatitis B was significantly lower than the mean concentration in the healthy group, while in patients with chronic hepatitis C, it was significantly higher than that in healthy people and in patients suffering from chronic hepatitis B. There were no significant differences in total sialic acid concentrations in patients with chronic hepatitis B and C according to the grade of portal/periportal activity, the grade of lobular activity and the stage of fibrosis. We conclude that chronic viral hepatitis affects the total serum concentration of sialic acid. Moreover, the concentration of total sialic acid may be a useful marker to differentiate between chronic hepatitis B and C but is not useful for evaluation of the progression of these diseases.

The concentration of sialic acid in acute and chronic pancreatic diseases

The alteration of glycoprotein and glicolipids sialylation can cause increase in the serum concentration of sialic acid during the different pathological processes, including cancers and inflammatory diseases. The aim of this study was to determine the changes in the concentration of sialic acids in the serum of patients with pancreatic diseases. It has been shown a significant increase in the concentration of TSA, LSA and FSA in all pancreatic diseases in comparison to the healthy subjects, except the LSA in chronic pancreatitis. In contrast to the FSA, the TSA and LSA concentrations were significantly different between pancreatic diseases. There were no differences in sialic acids concentration according to the location of tumors in the pancreas and the severity of cancer. All sialic acids have a high diagnostic power in primary pancreatic cancers. The diagnostic sensitivity and specificity of LSA in cancers were comparable to that of CA19-9. These results indicate a possibility of TSA, LSA and FSA using in the diagnosis of pancreatic diseases. Among sialic acids, LSA has the greatest usefulness in the diagnosis and differentiation of pancreatic diseases. Its concentration can be useful in differentiating between pancreatic cancer and pancreatitis. The high diagnostic power of LSA, comparable with CA19-9, suggest the possibility of its use as a non-specific marker of pancreatic cancer.

The relationship between serum sialic acid and high-sensitivity C-reactive protein with prehypertension

BackgroundThe aim of our study was to evaluate the serum concentration of sialic acid (SA) and high-sensitivity C-reactive protein (hs-CRP) in prehypertensive patients and the possible correlations between these 2 factors with blood pressure in such patients.Material/MethodsWe studied 61 prehypertensive patients, 70 hypertensive patients, and 50 controls with normal blood pressure. Lipid profile, hs-CRP, SA, and body mass index (BMI) were estimated in all groups. Associations between SA and hs-CRP and blood pressure were analyzed using multiple linear regressions.ResultsSA and hs-CRP levels were higher in the prehypertension group than that in the control group and were lower than that in the hypertension group. Multiple linear regression demonstrated that fasting glucose, BMI, SA, and hs-CRP correlated with systolic blood pressure and that low-density lipoprotein, BMI, SA, and hs-CRP correlated independently with diastolic pressure (P<0.05).ConclusionsOur findings suggest that in prehypertension, there is an association between serum SA and hs-CRP levels and blood pressure.

Association between sialic acid and high sensitivity C-reactive protein in prehypertension patients

Objective To evaluate the serum concentration of sialic acid (SA) and High sensitivity C-reactive protein (hs-CRP) in prehypertension patients and possible correlation of the two factors and blood pressure in prehypertension patients. Methods 61 prehypertension patients,70 hypertension patients and 50 healthy controls were included.Lipid profile,hs-CRP,SA,and body mass index (BMI) were estimated in all the groups.Associations between SA and hs-CRP and blood pressure were analyzed by multiple linear regressions. Results The levels of SA and hs-CRP were higher in the prehypertension group than those in the normal group and lower than those in the hypertension group (P<0.05).There was significant difference in systolic blood pressure (SBP),diastolic pressure (DBP),BMI and HDL among the three groups (P<0.05).There was significant difference between the prehypertension group and the hypertension group in LDL,TC and FBG.Multiple linear regression showed that FBG,BMI,SA and hs-CRP were correlated with SBP independently while LDL,BMI,SA and hs-CRP were correlated with DBP independently (P<0.05). Conclusions The findings of the present study suggest that,there is an association between blood pressure and the levels of serum SA and hs-CRP which might be used as screening biomarkers in prehypertension.(Chin J Lab Med,2013,36:516-518) Key words: N-acetylneuraminic acid; C-reactive protein; Blood pressure; Hypertension

Serum Sialic Acid as a Marker of Pancreatic Cancers

The carbohydrate alterations in sialoglycoproteins and sialoglycolipids cause the high serum concentration of sialic acid in many types of cancers. The aim of this study was to evaluate the diagnostic accuracy of total sialic acid (TSA), lipid-bound sialic acid (LSA), and free sialic acid (FSA) in patients with primary pancreatic cancers. TSA and LSA concentrations in the sera of 42 patients were measured by the enzymatic and FSA by the thiobarbituric method. The mean levels of TSA, LSA, and FSA in the sera of patients with pancreatic cancers were significantly higher than in controls. Taking into consideration the size and the location of the tumors, regional lymph node and distant metastases, there were no differences in TSA, FSA, and CA 19-9 levels. However, the location of tumors in the pancreas affects LSA levels. The sialic acids, contrary to CA 19-9, are not useful tools in the differential diagnosis of tumors and non-malignant diseases of the pancreas. LSA has the highest sensitivity, negative predictive value, accuracy, and the ability to discriminate cancer patients from healthy controls. The diagnostic power of LSA is similar to CA 19-9. We suggest that LSA can be useful in the diagnosis and evaluation of the tumor location in patients with primary pancreatic cancers.

Serum sialic acid changes in type 2 diabetic patients on metformin or rosiglitazone treatment

Serum sialic acid is a recently investigated potential risk-marker for cardiovascular complications. There is a known association between sialic acid and cardiovascular complications in diabetes mellitus. We aimed to investigate the effect of antidiabetic drugs on the serum concentration of sialic acid. We investigated the effect of metformin and rosiglitazone on the concentration of sialic acid in 120 type 2 diabetic patients, divided into a group (n = 60) receiving metformin and a group (n = 60) receiving rosiglitazone treatment. Serum sialic acid was significantly higher in patients on rosiglitazone (66·90 ± 8·80 mg/dL vs. 57·6 ± 8·46 mg/dL, P < 0·01) and metformin (61·95 ± 10·49 mg/dL vs. 57·6 ± 8·46 mg/dL, P < 0·04) when compared with control subjects. In addition, rosiglitazone-treated patients showed a significant increase in cardiovascular risk factors, notably total cholesterol (246·45 ± 20·2 mg/dL vs. 170·6 ± 15·1 mg/dL, P = 0·01), triglyceride (178 ± 9·20 mg/dL vs. 149·35 ± 6·31 mg/dL, P < 0·04) and glycohemoglobin (HbA1-c) concentration (8·17 ± 1·43% vs. 4·38 ± 0·96%, P < 0·02) compared with normal control subjects. The patients on metformin also showed significantly higher levels of serum glucose (133·7 ± 9·63 mg/dL vs. 88·35 ± 6·31 mg/dL, P < 0·04) and glycohemoglobin (HbA1-c) (8·23 ± 1·75% vs. 4·38 ± 0·96%, P < 0·02) when compared with control subjects. Comparison of the two groups of patients revealed a significantly higher serum sialic acid (66·90 ± 8·80 mg/dL vs. 61·95 ± 10·49 mg/dL, P < 0·05), total cholesterol (246·45 ± 20·2 mg/dL vs. 192 ± 14·23 mg/dL, P < 0·02) and triglyceride (178 ± 9·20 mg/dL vs. 158 ± 14·51mg/dL, P < 0·05) concentrations in the rosiglitazone-treated patients. This study suggests significantly higher levels of serum sialic acid and other cardiovascular risk factors in rosiglitazone-treated patients than in metformin-treated patients. The lower sialic acid concentration may explain a better metformin antidiabetic effect than with rosiglitazone.

口こう領域の急性細菌感染症における血清シアル酸

Serum sialic acid in patients with acute oral bacterial infections and healthy parsons was measured by enzymatic method. Significant raised levels of serum sialic acid were found in patients with acute infections as compared with healthy persons. Serum levels of sialic acid corresponded with the clinical condition of infections diseases and recovered normally with clinical improvement. Serum concentrations of sialic acid were well correlated with those of C-reactive protein and numbers of white blood cells. In addition, serum sialic acid significantly increased postoperatively.As human serum does not contain free sialic acid and sialic acid almost binds to glycoprotein such as C-reactive protein, acid glycoprotein, and so on, these results suggest that raised levels of serum sialic acid may be caused by the increase of acute phase proteins. Therefore, measurement of serum sialic acid is thought to be useful as a marker which reflects the clinical condition of infections diseases rather than infections themselves.

牛の血中シアル酸およびムコ蛋白の測定法と臨床応用

Sialic acid (SA) in bovine blood was assayed by five methods: the enzyme, the resorcinol, the thiobarbituric acid, Ehrlich's, and Hess'. There were highly significant statistical correlations among the values obtained by these methods. The plasma concentration of SA measured by the enzyme method and that of mucoprotein (MP) measured by the Coomasie Brilliant Blue G-250 method were 51.6±7.6mg/dl and 111.3±33.4mg/dl, respectively, in 136 healthy adult cattle. The plasma level of SA was higher in 138 bovine neonates during 14 postnatal days than in normal adult cattle, and that of MP in the former during 35 postnatal days.The serum concentrations of SA and MP were measured in 206 cattle affected with some inflammatory diseases diagnosed by meat-inspecting or practicing veterinarians. They were much higher in cattle with pyemia and endocarditis verrucosa and higher in those with liver abscess, nephritis, arthritis and mastitis than in normal cattle. They showed a difinite pattern in cattle having received laparotomy during a postoperative period till repair. As indicators for the diagnosis of an inflammatory disease and for the condition of postoperative course in cattle, the assay of both substances seemed to be very useful.